Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2010
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company has no approved products and generates revenue primarily through collaborative research agreements and licensing. Key programs include elagolix (endometriosis) and GPR119 agonists (Type II diabetes).
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2010 |
Six Months Ended June 30, 2009 |
|---|---|---|
| Total Revenues | $5,396 | $1,480 |
| Net Loss | $(13,788) | $(34,945) |
| Net Loss Per Share (Basic/Diluted) | $(0.27) | $(0.90) |
| Operating Cash Flow | $57,005 | $(28,021) |
| Cash and Cash Equivalents (End of Period) | $95,120 | $38,615 |
| Total Investments | $39,137 | $22,546 |
| Total Assets | $155,044 | $70,818 |
| Accumulated Deficit | $(768,089) | $(754,301) |
Note: The company reported no debt obligations other than lease liabilities and deferred revenue obligations. Liquidity is supported by cash, investments, and a Committed Equity Financing Facility (CEFF).
Material Changes vs. Prior Period
- Revenue Surge: Total revenue increased 265% year-over-year (from $1.48M to $5.40M) driven by new collaboration agreements with Abbott and Boehringer Ingelheim. This included $2.6M in amortized upfront license fees and $1.3M in sponsored development reimbursement.
- Reduced Net Loss: Net loss decreased significantly from $34.9M to $13.8M, attributed to higher revenues and cost-cutting measures from a restructuring program implemented in 2009.
- Operating Cash Flow Reversal: Operating cash flow swung from a use of $28.0M in 2009 to a provision of $57.0M in 2010. This was primarily due to a $75.0M upfront payment received from Abbott.
- Balance Sheet Expansion: Total assets more than doubled from $70.8M to $155.0M, reflecting the influx of cash from the Abbott deal and a public stock offering in March 2010 ($21.4M net proceeds).
- Expense Reduction: R&D expenses decreased by $6.8M and G&A expenses decreased by $2.7M compared to the prior six-month period, largely due to personnel reductions and expense management.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management expects to incur operating losses for the foreseeable future as product candidates advance through clinical development. The company believes current capital resources, combined with future collaboration payments, are sufficient to fund operations for at least the next 12 months. No specific financial guidance was provided for future quarters.
Key Risks and Contingencies:
- Clinical Trial Failure: Product candidates may fail to demonstrate safety or efficacy, delaying or preventing regulatory approval.
- Collaboration Dependency: The company relies heavily on partners (Abbott, Boehringer Ingelheim, etc.) for funding and commercialization. Termination of these agreements could severely impact liquidity.
- Liquidity of Investments: The company holds $12.3M in auction rate securities (ARS). While $9.1M was sold at par shortly after the period end, $3.2M remains illiquid and is carried at a fair value discount ($2.9M) due to market conditions.
- Real Estate Obligations: The company has a sale-leaseback arrangement for its headquarters. It vacated the "Front Building" but retains obligations for rent differentials and operating expenses through 2019, with a remaining cease-use liability of $9.5M.
- Indiplon Uncertainty: Future development of the insomnia drug candidate indiplon remains uncertain following an FDA "Approvable Letter" in 2007 that required additional studies.
Investor Verification Checklist
- Abbott Collaboration Terms: Verify the amortization schedule for the $75M upfront payment and the specific milestones required for the remaining $530M in potential payments.
- Auction Rate Securities (ARS): Confirm the current liquidity status and fair value of the remaining $3.2M ARS position, as valuation relies on significant unobservable inputs (Level 3).
- Real Estate Liability: Review the specific cash flow requirements for the "rent differential" payments on the vacated Front Building through 2019.
- CEFF Availability: Assess the conditions under which the $75M Committed Equity Financing Facility with Kingsbridge Capital can be accessed, noting the minimum share price threshold of $1.00.
- Indiplon Status: Monitor any updates regarding the resubmission of the New Drug Application (NDA) for indiplon and associated costs.